SWOG S-1602 Analysis Suggests Tokyo-172 Strain of BCG Is Noninferior to TICE Strain in the Treatment of NMIBC
Abstract
A comparison of efficacy outcomes from 2 different Bacillus Calmette-Guérin (BCG) strains for the treatment of non–muscle-invasive bladder cancer (NMIBC) found that the Tokyo-172 strain is noninferior to the standard-of-care TICE strain, according to data from the phase 3 SWOG S-1602 trial (LBA629). The results offer the possibility of another BCG therapy option and thus expanded treatment access for patients with NMIBC.
Fields of Study & Subjects
Bladder and Urothelial Cancer Treatments
Urinary Bladder and Prostate Research
Urinary Tract Infections Management
Publication details
- Journal / source
- Default Digital Object Group
- Publication date
- 27 February 2026
- Language
- EN
- Document type
- Dataset